Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m(2) given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m(2) IV weekly...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ravandi, Farhad, O'Brien, Susan, Jorgensen, Jeffrey, Pierce, Sherry, Faderl, Stefan, Ferrajoli, Alessandra, Koller, Charles, Challagundla, Pramoda, York, Sergernne, Brandt, Mark, Luthra, Rajyalakshmi, Burger, Jan, Thomas, Deborah, Keating, Michael, Kantarjian, Hagop
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2011
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081440/
https://ncbi.nlm.nih.gov/pubmed/21821712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-351502
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires